WO2022270589A1 - ラッカーゼ - Google Patents
ラッカーゼ Download PDFInfo
- Publication number
- WO2022270589A1 WO2022270589A1 PCT/JP2022/025137 JP2022025137W WO2022270589A1 WO 2022270589 A1 WO2022270589 A1 WO 2022270589A1 JP 2022025137 W JP2022025137 W JP 2022025137W WO 2022270589 A1 WO2022270589 A1 WO 2022270589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laccase
- protein
- amino acid
- present
- acid sequence
- Prior art date
Links
- 108010029541 Laccase Proteins 0.000 title claims abstract description 145
- 230000000694 effects Effects 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 235000018102 proteins Nutrition 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 150000001413 amino acids Chemical group 0.000 claims description 50
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 23
- 238000007254 oxidation reaction Methods 0.000 claims description 18
- 239000012770 industrial material Substances 0.000 claims description 15
- 239000002440 industrial waste Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 14
- 230000003647 oxidation Effects 0.000 claims description 12
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 6
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000005487 catechin Nutrition 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 3
- 229940074360 caffeic acid Drugs 0.000 claims description 3
- 235000004883 caffeic acid Nutrition 0.000 claims description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 claims description 2
- 239000000306 component Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 241001159194 Paramyrothecium sp. Species 0.000 abstract description 30
- 239000003513 alkali Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 47
- 229940088598 enzyme Drugs 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 29
- 238000004132 cross linking Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 21
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 108010073771 Soybean Proteins Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 108010084695 Pea Proteins Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000019702 pea protein Nutrition 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 235000021067 refined food Nutrition 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 239000006171 Britton–Robinson buffer Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010064851 Plant Proteins Proteins 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000021118 plant-derived protein Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DXRKLUVKXMAMOV-UHFFFAOYSA-N 3-heptadecylcatechol Chemical compound CCCCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DXRKLUVKXMAMOV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010073324 Glutaminase Proteins 0.000 description 2
- 102000009127 Glutaminase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000222355 Trametes versicolor Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 1
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000123650 Botrytis cinerea Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000043368 Multicopper oxidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- -1 methoxy-substituted phenols Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 108700020788 multicopper oxidase Proteins 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0061—Laccase (1.10.3.2)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03002—Laccase (1.10.3.2)
Definitions
- the present invention relates to a novel laccase.
- Laccase is an enzyme that belongs to multicopper oxidase, and catalyzes a reaction that oxidizes a substrate and uses the surplus electrons to reduce oxygen to four electrons to produce water.
- Substrates to be oxidized by laccase typically include diphenols, as well as methoxy-substituted phenols and diamines. Since such catalytic ability can be applied to various chemical reactions, it is expected to be used in many industrial fields. Laccase is known to exist in microorganisms, plants and animals.
- Patent Document 1 describes a thermostable laccase derived from the Trametes versicolor TV-1 strain, which exhibits the best laccase activity at pH 2.
- WO 2005/010000 discloses the pH range in which laccases derived from Botrytis cinerea, Trametes versicolor, or other microbial sources, as well as laccases that can be purchased from commercial sources and/or produced using recombinant technology, exhibit activity. is described as being between pH 3 and pH 7.
- Patent Document 3 describes that the optimum pH of laccase derived from microorganisms belonging to the genus Streptomyces is about 4.5, and that the activity is lost at pH 6.5.
- laccase is expected to be widely applied in industry. Its application mode also includes the case of catalyzing an oxidation reaction under alkaline conditions.
- laccases produced on an industrial scale and put into practical use have an action pH in the acidic to weakly acidic range, and cannot be used in the alkaline range in particular.
- conventional laccases are limited in the pH range in which they exhibit activity, and thus cannot sufficiently meet the application conditions expected in the industrial world.
- an object of the present invention is to provide a laccase that exhibits excellent activity in a pH range including an alkaline range.
- Section 1 A laccase consisting of a polypeptide shown in any of the following (a) to (c): (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1; (b) in the amino acid sequence shown in SEQ ID NO: 1, consisting of an amino acid sequence in which one or several amino acids are substituted, added, inserted or deleted, and in a pH range including an alkaline range, wherein (a) A polypeptide having laccase activity equivalent to the polypeptide shown in; (c) a polypolypeptide consisting of an amino acid sequence having a sequence identity of 70% or more to the amino acid sequence shown in SEQ ID NO: 1 and having a laccase activity equivalent to that of the polypeptide shown in (a) above in a pH range including an alkaline range; peptide.
- Section 2. A DNA encoding the laccase according to Item 1.
- Item 3. An expression cassette or recombinant vector containing the DNA according to item 2.
- Section 4. A transformant obtained by transforming a host with the expression cassette or recombinant vector according to item 3.
- Item 5. A method for producing laccase, comprising a step of culturing the transformant according to item 4.
- Item 6. Item 1. An enzyme preparation containing the laccase according to item 1.
- Item 7. The enzyme preparation according to Item 6, which is used as a protein cross-linking agent.
- Item 8. Item 7.
- Item 9 A method for producing a crosslinked protein, comprising the step of allowing the laccase of Item 1 to act on the protein.
- Item 10. The production method according to Item 9, wherein the step is performed under alkaline conditions.
- Item 11. Item 11.
- Item 12. Oxidatively modified food or food or food material, which comprises the step of allowing the laccase described in Item 1 to act on food or food or food or food material, industrial material or industrial waste component, or pharmaceutical or scientific analysis material. , industrial materials or industrial waste components, or methods of manufacturing pharmaceutical or scientific analytical materials.
- laccase that exhibits excellent activity in a pH range including an alkaline range is provided.
- Paramyrothecium sp This is the result of confirming the cross-linking activity of the derived laccase for pea protein under various pH conditions including alkaline pH.
- Paramyrothecium sp This is the result of confirming the cross-linking activity of the derived laccase for soybean protein under various pH conditions including alkaline pH.
- Paramyrothecium sp This is the result of confirming the cross-linking activity of the derived laccase for wheat protein under various pH conditions including alkaline pH.
- Paramyrothecium sp It is the result of examining the protein cross-linking activity when using various mediators together with the derived laccase.
- Paramyrothecium sp. pH stability of derived laccase (MM13-F2103) is shown.
- Paramyrothecium sp Temperature stability of derived laccase (MM13-F2103) is shown. Paramyrothecium sp. Optimum pH of derived laccase (MM13-F2103) is shown. Paramyrothecium sp. Optimal temperature of derived laccase (MM13-F2103) is shown. Paramyrothecium sp. The appearance of the meat-like processed food (MM13-derived) produced using the derived laccase is shown in comparison with the appearance of the meat-like processed food (without enzyme treatment) produced without using the laccase.
- nonpolar amino acids include alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, and tryptophan.
- Uncharged amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- Acidic amino acids include aspartic acid and glutamic acid.
- Basic amino acids include lysine, arginine, and histidine.
- Laccase The laccase of the present invention comprises a polypeptide shown in any one of (a) to (c) below.
- SEQ ID NO: 1 is Paramyrothecium sp. 1 is the amino acid sequence of the laccase from which it was derived.
- polypeptides (b) and (c) are laccases similar in sequence to the amino acid sequence of the polypeptide (a) as a basic skeleton.
- the amino acid modification introduced into the polypeptide of (b) above may include only one type of modification (e.g., substitution) selected from substitutions, additions, insertions, and deletions. may include modifications (eg, substitutions and insertions) of
- the number of amino acids to be substituted, added, inserted or deleted may be one or more or several, for example 1 to 10, preferably 1 to 8, 1 to 6, 1 to 5, or 1 to 4, more preferably 1 to 3, particularly preferably 1, 2, or 1.
- sequence identity may be 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, and still more preferably 98%. Above, more preferably 99% or more, particularly preferably 99.5% or more, most preferably 99.8% or more.
- sequence identity refers to the sequence identity calculated by comparison with the amino acid sequence shown in SEQ ID NO: 1.
- sequence identity refers to the bl2seq program of BLAST PACKAGE [sgi32 bit edition, Version 2.0.12; available from National Center for Biotechnology Information (NCBI)] Microbiol.Lett., Vol.174, p247-250, 1999).
- NCBI National Center for Biotechnology Information
- the parameters may be set to Gap insertion Cost value: 11 and Gap extension Cost value: 1.
- amino acid substitutions introduced into the amino acid sequence shown in SEQ ID NO: 1 include, for example, if the amino acid before substitution is a nonpolar amino acid, other nonpolar amino acids If the amino acid before substitution is a non-charged amino acid, it is substituted with another non-charged amino acid, if the amino acid before substitution is an acidic amino acid, it is substituted with another acidic amino acid, and the amino acid before substitution is If it is a basic amino acid, it may be substituted with other basic amino acids.
- amino acid addition When amino acid addition is introduced into the polypeptides of (b) and (c) above, examples of aspects of amino acid addition include addition of a methionine residue to the N-terminus, purification tags (e.g., binding properties such as oligohistidine) oligopeptide), and the like.
- purification tags e.g., binding properties such as oligohistidine
- polypeptides of (b) and (c) include not only polypeptides obtained by artificial mutation, but also naturally occurring mutations (mutants) based on individual differences in organisms from which the polypeptides are derived or differences in species. or variants) are also included.
- alkaline range refers to a pH range of more than 8.5, preferably pH 9 or higher.
- laccase activity refers to at least an activity that catalyzes a reaction that produces a crosslinked protein when a protein is used as a substrate (that is, protein crosslinking activity). Specifically, protein cross-linking activity is measured as follows.
- a supernatant is obtained as a protein solution by suspending and mixing the protein material in an alkaline pH buffer solution to 15% (w/v) and centrifuging. 100 ⁇ l of this protein solution, 97 ⁇ l of alkaline pH buffer, and 3 ⁇ l of 200 mM DL-catechin (as a mediator) are mixed to obtain a substrate solution. 20 ⁇ l of this substrate solution and 10 ⁇ l of enzyme (used so that the concentration of laccase is 1.7 ⁇ g/ml in protein concentration) are mixed and reacted at 37° C. for 18 hours. Thereafter, the reaction solution is diluted 10-fold and subjected to SDS-PAGE. The degree of protein cross-linking activity can be evaluated by the amount of high-molecular weight protein (that is, protein polymerized by cross-linking, appearing as a band at the origin) in SDS-PAGE.
- DNA A DNA encoding the laccase of the present invention (hereinafter sometimes referred to as "the DNA of the present invention") can be appropriately prepared and designed by those skilled in the art according to the amino acid sequence of the laccase of the present invention. .
- examples of the DNA encoding the laccase of the present invention include DNA shown in any of (i) to (iii) below.
- DNA consisting of the base sequence shown in SEQ ID NO: 2; (ii) a DNA comprising a nucleotide sequence that hybridizes under stringent conditions with a DNA comprising a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 2; (iii) A DNA comprising a nucleotide sequence having 70% or more homology to the nucleotide sequence shown in SEQ ID NO:2.
- the nucleotide sequence shown in SEQ ID NO: 2 is a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO: 1.
- the DNAs (ii) and (iii) are DNAs similar in sequence to the base sequence of the DNA (i).
- stringent conditions means 0.5% SDS, 5 ⁇ Denhartz's, 0.1% bovine serum albumin (BSA), 0.1% polyvinylpyrrolidone, 0.1% Ficoll 400] and 100 ⁇ g/ml salmon sperm DNA in 6xSSC (1xSSC is 0.15M NaCl, 0.015M sodium citrate, pH 7.0) at 50-65°C. Refers to conditions for keeping warm for 4 hours to overnight.
- Hybridization under stringent conditions is specifically performed by the following method. That is, a nylon membrane on which a DNA library or cDNA library was immobilized was prepared and incubated at 65° C. in a prehybridization solution containing 6 ⁇ SSC, 0.5% SDS, 5 ⁇ Denhardts, 100 ⁇ g/ml salmon sperm DNA. Block the nylon membrane. After that, each 32 P-labeled probe is added and incubated overnight at 65°C. This nylon membrane was placed in 6 ⁇ SSC at room temperature for 10 minutes, in 2 ⁇ SSC containing 0.1% SDS at room temperature for 10 minutes, and in 0.2 ⁇ SSC containing 0.1% SDS at 45° C. for 30 minutes. After washing, autoradiography can be performed to detect DNA specifically hybridizing with the probes.
- the homology may be 70% or higher, preferably 80% or higher, more preferably 90% or higher, even more preferably 95% or higher, still more preferably 98% or higher, and more preferably 98% or higher. More preferably 99% or more, particularly preferably 99.5% or more, most preferably 99.8% or more.
- the "homology" of the nucleotide sequence refers to the BLAST PACKAGE [sgi32 bitedition, Version 2.0.12; Madden, FEMS Microbiol. Lett., Vol. 174, 247-250, 1999).
- the parameters may be set to Gap insertion Cost value: 11 and Gap extension Cost value: 1.
- a base sequence encoding a purification tag for example, a binding oligopeptide such as oligohistidine
- a purification tag for example, a binding oligopeptide such as oligohistidine
- the DNA of the present invention can be prepared, for example, by using, as a template, a DNA encoding any of the polypeptides of (a) to (c), and at least one of the polypeptides of (a) to (c). can be obtained by obtaining the region encoding the by PCR or the like.
- the DNA encoding the laccase of the present invention can be artificially synthesized by a gene synthesis method.
- a specific mutation is introduced into a specific site of a base sequence
- the method of introducing mutation is known, and for example, site-specific mutagenesis of DNA can be used.
- a specific method for converting bases in DNA for example, a commercially available kit can be used.
- DNA with mutations introduced into the base sequence can be confirmed using a DNA sequencer. Once the nucleotide sequence is determined, then chemical synthesis, PCR using the cloned probe as a template, or hybridization using a DNA fragment having the nucleotide sequence as a probe to obtain the DNA encoding the laccase. can be done.
- the DNA of the present invention is preferably one whose codon usage frequency is optimized for the host.
- a DNA whose codon usage frequency is optimized for E. coli is suitable.
- expression cassette or recombinant vector containing DNA encoding the laccase of the present invention (hereinafter also referred to as "expression cassette of the present invention” or “recombinant vector of the present invention”) is It includes DNA encoding the laccase of the invention.
- the expression cassette or recombinant vector of the present invention can be obtained by ligating a promoter and a terminator to the DNA of the present invention, or by inserting the expression cassette or the DNA of the present invention into an expression vector.
- the expression cassette or recombinant vector of the present invention may contain transcription elements such as promoters and terminators, as well as enhancers, CCAAT boxes, TATA boxes, and SPI sites, as required. These regulatory factors need only be operably linked to the DNA of the present invention.
- operably linked means that various control factors that regulate the DNA of the present invention and the DNA of the present invention are linked in a state in which they are operable in host cells.
- the expression cassette or recombinant vector of the present invention may be configured to further contain a protease recognition sequence and an N-terminal sequence and/or a C-terminal sequence.
- expression vector those constructed for genetic recombination from phages, plasmids, or viruses that are capable of autonomous replication within the host are suitable. Such expression vectors are known, and suitable combinations with host cells can be appropriately selected and used by those skilled in the art.
- pBluescript (pBS) II SK (-) manufactured by Stratagene
- pSTV-based vector manufactured by Takara Bio
- pUC-based vector manufactured by Takara Bio
- pET-based vector Merck
- pGEX vector GE Healthcare
- pHY300PLK Tekara Bio
- pUB110 Mckenzie, T. et al., 1986, Plasmid 15 (2 ), pp.
- pBR322 manufactured by Takara Bio
- pRS403 manufactured by Stratagene
- pMW218/219 manufactured by Nippon Gene.
- pUC19 manufactured by Takara Bio Inc.
- P66 Chlamydomonas Center
- P-322 Cholamydomonas Center
- pPha-T1 Yangmin Gong, et al., Journal of Basic Microbiology, 2011, vol.51, p.666-672
- pJET1 manufactured by Cosmo Bio
- pRI-based vectors manufactured by Takara Bio
- pBI-based vectors manufactured by Clontech
- IN3-based vectors manufactured by Implanta Innovations
- Transformant A transformant (hereinafter sometimes referred to as “the transformant of the present invention") is obtained by transforming a host with the expression cassette or recombination vector of the present invention.
- the host used for the production of the transformant is not particularly limited as long as it can introduce a gene, can grow autonomously, and can express the trait of the gene of the present invention.
- Examples include Escherichia coli.
- Preferable examples include bacteria belonging to the genus Escherichia such as Bacillus subtilis, Pseudomonas such as Pseudomonas putida; , but animal cells, insect cells, plant cells and the like may also be used. Among these, Escherichia coli is particularly preferred.
- Paramyrothecium sp. may be
- the transformant of the present invention can be obtained by introducing the expression cassette or recombinant vector of the present invention into a host.
- the place where the DNA of the present invention is introduced is not particularly limited as long as the gene of interest can be expressed, and may be on a plasmid or genome.
- Specific methods for introducing the expression cassette of the present invention or the recombinant vector of the present invention include, for example, recombinant vector methods and genome editing methods.
- the conditions for introducing the expression cassette or recombinant vector of the present invention into the host may be appropriately set according to the type of host.
- the host is a microorganism, for example, a method using competent cells by calcium ion treatment, an electroporation method, a spheroplast method, a lithium acetate method and the like can be used.
- the host is an animal cell, for example, the electroporation method, calcium phosphate method, lipofection method and the like can be used.
- the host is an insect cell, for example, the calcium phosphate method, lipofection method, electroporation method and the like can be used.
- the host is a plant cell, for example, the electroporation method, the Agrobacterium method, the particle gun method, the PEG method and the like can be used.
- the laccase of the present invention can be produced by culturing the transformant of the present invention. Moreover, the laccase of the present invention is Paramyrothecium sp. It can also be produced by culturing itself (not transformed).
- the culture conditions for the transformants or derived bacteria or derived cells of the present invention may be appropriately set in consideration of the nutritional and physiological properties of the host or derived bacteria or derived cells, preferably liquid culture. Further, in the case of industrial production, aeration and agitation culture is preferable.
- the transformant or derived bacteria or derived cells of the present invention are cultured, and the culture solution is collected by a method such as centrifugation to recover the culture supernatant or cultured cells or cultured cells. If the laccase of the present invention is accumulated in cultured bacteria or cultured cells, the bacteria or cells are treated with ultrasonic waves, a mechanical method such as French press, or a lytic enzyme such as lysozyme.
- the water-soluble fraction containing the laccase of the present invention can be obtained by solubilization by using an enzyme such as protease or a surfactant such as sodium dodecyl sulfate (SDS).
- the expressed laccase of the present invention may be secreted into the culture medium.
- the culture medium, the water-soluble fraction, or the protease-treated product containing the laccase of the present invention obtained as described above may be directly subjected to a purification treatment, but the culture medium, the water-soluble fraction, or the protease-treated product may be purified. After concentrating the laccase of the present invention in the product, it may be subjected to a purification treatment.
- Concentration can be performed, for example, by vacuum concentration, membrane concentration, salting-out treatment, fractional precipitation using a hydrophilic organic solvent (eg, methanol, ethanol, and acetone), or the like.
- a hydrophilic organic solvent eg, methanol, ethanol, and acetone
- the purification treatment of the laccase of the present invention can be performed, for example, by appropriately combining methods such as gel filtration, hydrophobic chromatography, ion exchange chromatography, and affinity chromatography.
- the laccase of the present invention thus purified may be pulverized by freeze-drying, vacuum-drying, spray-drying, etc., if necessary.
- the laccase of the present invention can be provided in the form of an enzyme preparation. Accordingly, the present invention also provides an enzyme preparation containing the above-described laccase of the present invention.
- the content of the laccase of the present invention in the enzyme preparation of the present invention is not particularly limited, and can be appropriately set within a range in which the laccase activity is exhibited.
- the enzyme preparation of the present invention may contain other ingredients in addition to the laccase of the present invention to the extent that the effects of the present invention are not affected.
- examples of other components include enzymes other than the laccase of the present invention, mediators, additives, and culture residue produced by the above production method.
- enzymes can be appropriately determined depending on the intended use. galactosidase, ⁇ -galactosidase), protease (acid protease, neutral protease, alkaline protease), peptidase (leucine peptidase, aminopeptidase), lipase, esterase, cellulase, phosphatase (acid phosphatase, alkaline phosphatase), nuclease, deaminase, oxidase, Dehydrogenase (other than the above active ingredients), glutaminase, pectinase, catalase, dextranase, transglutaminase, protein deamidase, pullulanase and the like. These other enzymes may be contained singly or in combination of multiple types.
- mediators examples include 3-(3,4-dihydroxyphenyl)alanine (DOPA), catechin, and caffeine. These mediators may be contained singly or in combination of multiple types.
- DOPA 3-(3,4-dihydroxyphenyl)alanine
- catechin catechin
- caffeine caffeine
- the additive can be appropriately determined according to the use of the laccase of the present invention and the formulation form of the enzyme preparation. Salt solution etc. are mentioned.
- Excipients include starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, sucrose, glycerol, pectin and the like.
- Buffers include phosphate, citrate, acetate and the like.
- Stabilizers include propylene glycol, ascorbic acid and the like.
- Preservatives include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben and the like.
- antiseptics include ethanol, benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and the like.
- the culture residue includes medium-derived components, contaminant proteins, fungal components, cell components, and the like.
- the formulation form of the enzyme preparation of the present invention is not particularly limited, and examples thereof include liquid and solid forms (powder, granules, etc.). These formulation forms of enzyme preparations can be prepared by generally known methods.
- the enzyme preparation of the present invention can be used as a cross-linking agent for proteins, and can also be used for the oxidative modification of foods and beverages, materials for foods and beverages, industrial materials, industrial waste components, or materials for pharmaceuticals or scientific analysis. It can also be used as a substance.
- the target of oxidative modification and the details of oxidative modification are as described in "7. Use of laccase" below.
- laccases of the present invention can be used in any application that utilizes a variety of incidental chemical reactions resulting from oxidation of a substrate and/or radical species of reaction intermediates produced by the oxidation.
- oxidation reactions or concomitant chemical reactions are oxidation of phenolic compounds such as o-, p-diphenol, urushiol, laccol; oxidation of aromatic amines such as p-phenylenediamine; decomposition of lignin. ; tyrosine side chain (phenolic hydroxyl group), cysteine side chain (sulfhydryl group), lysine side chain ( ⁇ -amino group), histidine side chain (imidazole group), etc. be done.
- chemically changing a substrate by such an oxidation reaction of laccase and accompanying chemical reactions is also referred to as "oxidative modification”.
- the present invention also provides a method for producing a crosslinked protein, comprising the step of allowing the laccase of the present invention to act on the protein.
- mediators such as 3-(3,4-dihydroxyphenyl)alanine (DOPA), catechin, and caffeine are replaced with laccase in the process. It is preferable to use in combination with These mediators may be contained singly or in combination of multiple types.
- the reaction conditions e.g., amount of enzyme, reaction time, reaction pH, reaction temperature, etc.
- the reaction conditions e.g., amount of enzyme, reaction time, reaction pH, reaction temperature, etc.
- the desired degree of protein crosslinking is achieved.
- those skilled in the art can appropriately set it according to the type and/or concentration of the laccase of the present invention, the type and/or concentration of the protein, and/or the desired degree of protein cross-linking.
- the reaction pH is preferably above 8.5, more preferably 9 or above.
- the upper limit of the reaction pH is, for example, 12 or less, preferably 11 or less, more preferably 10 or less, and still more preferably 9.5 or less.
- the laccase used in the method for producing a crosslinked protein of the present invention preferably exhibits excellent laccase activity not only in the alkaline range but also in the neutral range. , or 8 or more.
- the upper limit of the reaction pH is, for example, 12 or less, preferably 11 or less, more preferably 10 or less, still more preferably 9.5 or less, 9 or less, or 8.5 or less.
- reaction temperature is 4 to 45°C, more preferably 25 to 40°C.
- Process for producing oxidatively modified foods and beverages, materials for foods, industrial materials, industrial waste components, or materials for pharmaceuticals or scientific analysis examples include industrial materials or industrial waste components, or materials for pharmaceuticals or scientific analysis. Therefore, the present invention further provides an oxidatively modified food or drink material, an industrial material or an industrial waste component, or a pharmaceutical or scientific analysis material, which comprises the step of allowing the laccase of the present invention to act. Also provided is a method for producing food or beverage materials, industrial materials or industrial waste components, or pharmaceutical or scientific analysis materials.
- Examples of oxidative modification of food or food materials include cross-linking of proteins, improvement of binding properties of textured vegetable proteins, thickening or gelling of foods, browning treatment of black tea, removal of bitterness and astringency of foods. etc.
- Examples of oxidative modification of industrial materials or components of industrial waste include production of artificial lacquer, removal of lignin from pulp, detoxification of waste liquids containing highly toxic phenolic compounds and/or aromatic amines, and synthesis of organic compounds. , production of adhesives, and synthesis of concrete admixtures.
- Examples of oxidative modification of materials for pharmaceuticals or scientific analysis include conversion of analyte components into sensing components, cross-linking of analyte proteins, and the like.
- the step Preferably, the mediator is used in combination with laccase.
- mediators that can be used are as described above in “7-1. Production method of crosslinked protein”.
- reaction conditions for example, the amount of enzyme, reaction time, reaction pH, reaction temperature, etc.
- reaction pH and reaction temperature are as described in the above “7-1. Method for producing crosslinked protein”.
- Test Example 1 Culture and Enzyme Purification (1-1) Culture and Filtration Paramyrothecium sp. grown on potato dextrose agar medium at 30° C. for 3 days in a 500 ml shake flask containing 100 ml of the laccase production medium shown in Table 1. A 1 cm square section of a colony of the MM13-F2103 strain (country of origin: Sri) was inoculated and cultured with reciprocating shaking (140 r/min) at 30° C. for 3 days. After solid-liquid separation of the culture solution by centrifugation, the supernatant was filtered off, and the collected filtrate was used as a crude enzyme solution.
- ⁇ Confirmation of laccase activity-oxidation of ABTS 20 ⁇ l of a 50 mM solution of ABTS (2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)) as substrate, 160 ⁇ l of 125 mM sodium phosphate buffer (pH 7.0), and the enzyme 20 ⁇ l of the solution was added to a microplate, mixed, reacted at 37°C for 15 minutes, and the absorbance at 405 nm was measured before and after the reaction. The presence of laccase activity was confirmed by confirming the oxidation of ABTS.
- Test Example 2 Evaluation of enzyme properties (2-1) Evaluation of laccase activity (protein cross-linking activity) Paramyrothecium sp.
- the purified laccase obtained from the MM13-F2103 strain and the comparative laccase "Laccase Y120" manufactured by Amano Enzyme Co., Ltd. (also referred to as LC-Y120) were obtained from the three plants shown in Table 2, respectively.
- Plant protein powder was adjusted to 15% (w/v) with a predetermined pH buffer [50 mM Na citrate buffer (pH 3.0 or 5.0), 50 mM Na phosphate buffer (pH 7.0), 0), or 50 mM Tris-HCl buffer (pH 9.0)] and mixed well, followed by solid-liquid separation by centrifugation at 12,000 x g for 5 minutes to obtain a supernatant as a protein solution. . 100 ⁇ l of this protein solution, 97 ⁇ l of the above-mentioned predetermined pH buffer solution, and 3 ⁇ l of 200 mM DL-catechin (mediator) were mixed to obtain a substrate solution.
- a predetermined pH buffer 50 mM Na citrate buffer (pH 3.0 or 5.0), 50 mM Na phosphate buffer (pH 7.0), 0), or 50 mM Tris-HCl buffer (pH 9.0)
- the amount of the crosslinked protein was evaluated by the number of "+". The greater the number of "+”s, the greater the amount of crosslinked protein produced. The results are shown in Figures 1-3.
- the amount of the crosslinked protein can also be quantified using image analysis software such as imageJ.
- the leftmost lane (lane 1 in FIGS. 1 and 2, blank lane in FIG. 3) represents the results of a control to which no enzyme was added, and the middle lane (lane 2 in FIGS. 1 and 2) , "LCY120" lane in FIG. 3) represents the results when the laccase for comparison was used, and the rightmost lane (lane 3 in FIGS. 1 and 2, "MM2103" lane in FIG. 3) represents Paramyrothecium sp. Shows the results when using the purified laccase obtained from the MM13-F2103 strain.
- the relative value of the enzyme activity value after pH treatment was derived as the residual activity (%) when the enzyme activity value at the treatment pH that showed the highest residual activity was taken as 100%.
- the results are shown in FIG. As is clear from FIG. 5, Paramyrothecium sp.
- the laccase obtained from the MM13-F2103 strain had significantly improved stability in the alkaline region compared to the commercially available laccase LC-Y120.
- the enzymatic activity value was measured by defining the enzymatic activity that catalyzes the oxidation of 1 ⁇ mol of ABTS per minute as 1 unit (U).
- a relative activity value was derived when the enzyme activity value at the optimum temperature of LC-Y120 was taken as 100%. The results are shown in FIG.
- Test Example 3 Sequence identification Paramyrothecium sp. Laccase obtained from strain MM13-F2103 was sequenced. As a result, the sequence (2018 bp) shown in SEQ ID NO: 3 as the gene sequence, the sequence (1764 bp) shown in SEQ ID NO: 2 as the coding region sequence, and the sequence (587 aa) shown in SEQ ID NO: 1 as the amino acid sequence were determined.
- Test Example 4 Improving Adhesion of Textured Vegetable Protein Granular soybean protein (manufactured by Marukome Co., Ltd.) was added with warm water (40° C.) of 5 times its weight and allowed to stand for 10 minutes to swell. After removing moisture, 25 g of swollen granular soybean protein was weighed. The swollen granular soybean protein was mixed with 2.75 g of powdered pea protein (NUTRALYS F85M manufactured by Rocket Co.), and Paramyrothecium sp. About 250 U (about 10 U per gram of swollen granular soy protein) of purified laccase obtained from strain MM13-F2103 was added to prepare a soy protein mixture. The soy protein mixture was mixed well and formed into a hamburger shape and allowed to stand at 25°C for 60 minutes. After baking in an oven at 190°C for 15 minutes, a meat-like processed food was obtained.
- NUTRALYS F85M powdered pea protein
- FIG. 9 shows a meat-like processed food (without enzyme treatment) obtained in the same manner except that laccase was not used. As shown in FIG. 9, no binding was observed in the case of no enzyme treatment, whereas binding was confirmed in the case of treatment with the laccase derived from the MM13 strain.
- Test Example 5 Thickening of protein solution
- the pea protein powder used in Test Example 2 was adjusted to 15% (w/v) with a buffer solution of a predetermined pH [50 mM Na citrate buffer (pH 3.0 or 5 .0), 50 mM Na phosphate buffer (pH 7.0), or 50 mM Tris-HCl buffer (pH 9.0)] to obtain a pea protein suspension.
- Paramyrothecium sp. was added to this pea protein suspension.
- Purified laccase obtained from MM13-F2103 strain or laccase LC-Y120 for comparison 0.1 mg / ml in terms of protein weight and 5 mg / ml protein glutaminase are added, pH 3, 5, 7, or The reaction was carried out at 37° C. for 18 hours under the conditions of 9.
- the properties of the reactants were evaluated as "-" when there was no change in physical properties, and as "+” when thickening was observed. Table 4 shows the results.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
項1. 下記(a)~(c)のいずれかに示すポリペプチドからなる、ラッカーゼ:
(a)配列番号1に示すアミノ酸配列からなるポリペプチド;
(b)配列番号1に示すアミノ酸配列において、1個又は数個のアミノ酸が置換、付加、挿入又は欠失されてなるアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド;
(c)配列番号1に示すアミノ酸配列に対する配列同一性が70%以上のアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド。
項2. 項1に記載のラッカーゼをコードするDNA。
項3. 項2に記載のDNAを含む発現カセット又は組換えベクター。
項4. 項3に記載の発現カセット又は組換えベクターを用いて宿主を形質転換して得られる形質転換体。
項5. 項4に記載の形質転換体を培養する工程を含む、ラッカーゼの製造方法。
項6. 項1に記載のラッカーゼを含む酵素製剤。
項7. タンパク質の架橋剤として用いられる、項6に記載の酵素製剤。
項8. 飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材の酸化改質剤として用いられる、項6に記載の酵素製剤。
項9. タンパク質に、項1に記載のラッカーゼを作用させる工程を含む、架橋タンパク質の製造方法。
項10. 前記工程をアルカリ性条件下で行う、項9に記載の製造方法。
項11. 前記工程において、前記ラッカーゼに、3-(3,4-ジヒドロキシフェニル)アラニン、カテキン、及びカフェイン酸からなる群より選択されるメディエータを併用する、項9または10に記載の製造方法。
項12. 飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材に、項1に記載のラッカーゼを作用させる工程を含む、酸化改質された飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材の製造方法。
本発明のラッカーゼは、下記(a)~(c)のいずれかに示すポリペプチドからなる。
(b)配列番号1に示すアミノ酸配列において、1個又は数個のアミノ酸が置換、付加、挿入又は欠失されてなるアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド;
(c)配列番号1に示すアミノ酸配列に対する配列同一性が70%以上のアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド。
以下、(a)~(c)のポリペプチドからなるラッカーゼについて詳述する。
本発明のラッカーゼをコードしているDNA(以下、「本発明のDNA」と表記することもある)は、当業者であれば、本発明のラッカーゼのアミノ酸配列に従って適宜調製及び設計することができる。
本発明のラッカーゼをコードしているDNAの塩基配列については、当業者であれば、本発明のラッカーゼにおいて述べたアミノ酸配列に従って適宜設計可能である。
(ii)配列番号2に示される塩基配列と相補的な塩基配列からなるDNAとストリンジェントな条件下でハイブリダイズするDNAの塩基配列からなるDNA;
(iii)配列番号2に示される塩基配列に対して70%以上の相同性を有する塩基配列からなるDNA。
以下、(i)~(iii)のDNAについて詳述する。
本発明のDNAは、例えば、前記(a)~(c)のいずれかのポリペプチドをコードしているDNAを鋳型として、少なくとも前記(a)~(c)のいずれかのポリペプチドをコードしている領域をPCR等によって取得することにより得ることができる。また、本発明のラッカーゼをコードしているDNAは、遺伝子の合成法によって人工合成することもできる。
本発明のラッカーゼをコードしているDNAを含む発現カセット又は組換えベクター(以下、「本発明の発現カセット」又は「本発明の組換えベクター」とも表記する)は、本発明のラッカーゼをコードするDNAを含む。本発明の発現カセット又は組換えベクターは、本発明のDNAにプロモーター及びターミネーターを連結することにより、又は、発現ベクターに本発明の発現カセット若しくは本発明のDNAを挿入することにより得ることができる。
本発明の発現カセット又は組換えベクターを用いて宿主を形質転換することによって、形質転換体(以下、「本発明の形質転換体」と表記することもある)が得られる。
本発明のラッカーゼは、前記本発明の形質転換体を培養することによって製造することができる。また、本発明のラッカーゼは、Paramyrothecium sp.そのもの(形質転換されていないもの)を培養することによって製造することもできる。
本発明のラッカーゼは、酵素製剤の形態で提供されることができる。したがって、本発明は、上記本発明のラッカーゼを含む酵素製剤も提供する。
本発明のラッカーゼは、基質の酸化反応及び/又は当該酸化反応により生成される反応中間体のラジカル種に起因する多様な付随的化学反応を利用する任意の用途に用いることができる。このような酸化反応又は付随的化学反応の例としては、o-,p-ジフェノール、ウルシオール、ラッコール等のフェノール性化合物の酸化;p-フェニレンジアミン等の芳香族アミンの酸化;リグニンの分解;チロシン側鎖(フェノール性水酸基)、システイン側鎖(スルフヒドリル基)、リジン側鎖(ε-アミノ基)、ヒスチジン側鎖(イミダゾール基)等の酸化されやすい官能基を有するタンパク質の架橋等が挙げられる。本明細書では、このようなラッカーゼの酸化反応及び付随的化学反応により基質を化学的に変化させることを、「酸化改質」とも記載する。
上記の酸化改質の態様の中でも、特に好ましくは、タンパク質の架橋により変化させることが挙げられる。従って、本発明は、タンパク質に上記の本発明のラッカーゼを作用させる工程を含む、架橋タンパク質の製造方法も提供する。
上記の酸化改質の対象物としては、飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材等が挙げられる。従って、本発明は、さらに、飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材に、上記の本発明のラッカーゼを作用させる工程を含む、酸化改質された飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材の製造方法も提供する。
(1-1)培養及びろ過
表1に示すラッカーゼ生産培地100mlを含む500ml容振とうフラスコに、ポテトデキストロース寒天培地にて30℃で3日間生育させたParamyrothecium sp. MM13-F2103株(原産地国:ミャンマー)コロニーの1cm角切片を接種し、30℃で3日間、往復振盪培養(140r/min)した。培養液を遠心分離により固液分離後、上清を濾別し、回収した濾液を粗酵素液とした。
粗酵素液を限外濾過により濃縮後、20mMリン酸Na緩衝液(pH7.0)+0.3M NaClに対して透析し、透析内液を得た。この透析内液を、上記緩衝液で平衡化したHiTrap Q Fast Flow(I.D.×L=1.6×2.5cm;Cytiva社製)に供した。上記カラムを同緩衝液50mlで洗浄後、NaCl濃度のリニアグラジエント(0.3~0.6M、50ml)により、カラムに吸着したラッカーゼを溶出させ、分画した。得られた各画分の一部について以下に示す方法でラッカーゼ活性の確認(ABTSの酸化及びタンパク質の架橋)を行い、両活性を有する画分を回収し、1次精製液とした。
1次精製液を、限外濾過により濃縮後、20mMリン酸Na緩衝液(pH7.0)+0.5M NaClに対して透析し、透析内液を得た。この透析内液を、HiLoad 16/600 Superdex 200 pg(I.D.×L=1.6×60cm;Cytiva社製)に供し、活性を有する画分を合わせて、20mMリン酸Na緩衝液(pH7.0)に対して透析し、精製ラッカーゼ溶液を得た。SDS-PAGEおよびNative-PAGEにて、精製を確認した。
基質としてのABTS(2,2´-アジノ-ビス-(3-エチルベンゾチアゾリン-6-スルホン酸))の50mM溶液を20μlと、125mMリン酸ナトリウム緩衝液(pH7.0)を160μlと、酵素液20μlとをマイクロプレートに添加して混合し、37℃で15分反応を行い、反応前後における405nmでの吸光度を測定した。ABTSの酸化を確認することで、ラッカーゼ活性の存在を確認した。
後述表2の3種の植物タンパク質粉末について、それぞれ、以下の操作を行った。植物タンパク質粉末を、15%(w/v)となるよう、50mMのリン酸Na緩衝液(pH7.0)に懸濁してよく混合した後、12,000×g、5分間の遠心により固液分離し、上清をタンパク質溶液として得た。このタンパク質溶液100μlと、50mMのリン酸Na緩衝液(pH7.0)97μlと、200mMのDL-カテキン(メディエータ)3μlとを混合し、これにより基質溶液を得た。この基質溶液20μlと酵素10μl(ラッカーゼの濃度が、DCプロテインアッセイ(Bio-Rad社製)を用いて定量されるタンパク質濃度で1.7μg/mlとなるように用いた。)とを混合し、37℃、18時間にて反応させた。その後、反応液を10倍希釈し、表2中に示したアプライ量をSDS-PAGEに供した。タンパク質架橋活性は、SDS-PAGEにおける高分子タンパク質(架橋により高分子化したタンパク質。原点におけるバンドとして表れる。)の存在により確認した。
(2-1)ラッカーゼ活性(タンパク質架橋活性)の評価
Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼと、比較用のラッカーゼである天野エンザイム(株)製「ラッカーゼ Y120」(LC-Y120とも記載する。)とについて、それぞれ、表2に示す3種の植物タンパク質それぞれに対する所定のpH(pH3.0、5.0、7.0及び9.0)でのタンパク質架橋活性を評価した。
Paramyrothecium sp. MM13-F2103株から得られたラッカーゼについて、50mMのTris-HCl緩衝液(pH9.0)のみを用いた点、メディエータを表3に記載のもの(但し100mMの濃度となるように用いた。)に変更した点、ラッカーゼの濃度をタンパク質濃度で33μg/mlとなるように用いた点、及び反応時間を1時間とした点を除き、上記「(1-2)ラッカーゼ活性(タンパク質架橋活性)の評価方法」と同様の操作を行うことで、各種メディエータによるタンパク質架橋促進効果を評価した。結果を図4に示す。図4中、各レーンの数字は、表3における数字に対応する。
Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼと、比較用のラッカーゼLC-Y120とを、それぞれpHが異なる50mM Britton-Robinson緩衝液(pH2~12)に溶解し、得られた酵素液を、4℃、1時間インキュベートすることでpH処理した。それぞれの酵素液について、上記(1-3)の「<ラッカーゼ活性の確認-ABTSの酸化>」と同様の操作を行った。1分間に1μmolのABTSの酸化を触媒する酵素活性を1ユニット(U)と定義して、酵素活性値を測定した。
Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼと、比較用のラッカーゼLC-Y120とを、それぞれ50mM Britton-Robinson緩衝液(pH7.0)に溶解し、得られた酵素液を、4℃、20℃、30℃、40℃、50℃、60℃、70℃又は80℃にて1時間インキュベートすることで温度処理した。温度処理前と処理後とにおけるそれぞれの酵素液について、酵素活性値を、上記(2-3)に記載した方法と同様にして測定し、温度処理前の酵素活性値を100%とした場合の温度処理後における酵素活性値の相対値を、残存活性(%)として導出した。結果を図6に示す。図6から明らかな通り、Paramyrothecium sp. MM13-F2103株から得られたラッカーゼは、40℃未満で高い安定性を示した。
Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼと、比較用のラッカーゼLC-Y120とをそれぞれ用い、50mMのリン酸Na緩衝液(pH7.0)の代わりに、pHが異なる50mMのBritton-Robinson緩衝液(pH2~12)を用いたことを除いて、上記(1-3)の「<ラッカーゼ活性の確認-ABTSの酸化>」と同様の操作を行った。1分間に1μmolのABTSの酸化を触媒する酵素活性を1ユニット(U)と定義して、酵素活性値を測定した。LC-Y120の至適pHにおける酵素活性値を100%とした場合の相対活性値を導出した。結果を図7に示す。図7から明らかな通り、Paramyrothecium sp. MM13-F2103株から得られたラッカーゼは、アルカリ域でも活性を呈していた。
Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼと、比較用のラッカーゼLC-Y120とを用い、反応温度を37℃の代わりに、4℃、20℃、30℃、40℃、50℃、60℃又は70℃で行い、50mMのリン酸Na緩衝液(pH7.0)の代わりに、各ラッカーゼの至適pHである50mMのBritton-Robinson緩衝液を使用した点を除いて、上記(1-3)の「<ラッカーゼ活性の確認-ABTSの酸化>」と同様の操作を行った。1分間に1μmolのABTSの酸化を触媒する酵素活性を1ユニット(U)と定義して、酵素活性値を測定した。LC-Y120の至適温度における酵素活性値を100%とした場合の相対活性値を導出した。結果を図8に示す。
Paramyrothecium sp. MM13-F2103株から得られたラッカーゼのシーケンスを行った。その結果、遺伝子配列として配列番号3に示す配列(2018bp)、コーディング領域配列として配列番号2に示す配列(1764bp)、及びアミノ酸配列として配列番号1に示す配列(587aa)を決定した。
粒状大豆蛋白(マルコメ株式会社製)に5倍重量の温水(40℃)を加え、10分間静置して膨潤させた。水分を除き、膨潤した粒状大豆蛋白を25g秤量した。膨潤した粒状大豆蛋白に、2.75gの粉末状エンドウ蛋白(ロケット社製NUTRALYS F85M)を混ぜ、Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼを約250U(膨潤粒状大豆蛋白1g当たり約10U)添加し、大豆タンパク質混合物を調製した。大豆タンパク質混合物をよく混合してハンバーグ状に成形し、25℃にて60分間静置した。オーブンにて190℃、15分の焼成工程を経て、肉様加工食品を得た。
試験例2で用いたエンドウ蛋白粉末を15%(w/v)となるように所定のpHの緩衝液[50mMのクエン酸Na緩衝液(pH3.0又は5.0)、50mMのリン酸Na緩衝液(pH7.0)、又は50mMのTris-HCl緩衝液(pH9.0)]に懸濁して、これをエンドウ蛋白懸濁液とした。このエンドウ蛋白懸濁液に、Paramyrothecium sp. MM13-F2103株から得られた精製ラッカーゼ、又は、比較用のラッカーゼLC-Y120をタンパク質重量換算量で0.1mg/mlと、プロテイングルタミナーゼを5mg/mlとを加え、pH3、5、7、又は9の条件下で、37℃にて18時間反応させた。反応物の性状について、物性に変化がない場合を「-」、増粘が認められた場合を「+」として評価した。結果を表4に示す。
Claims (12)
- 下記(a)~(c)のいずれかに示すポリペプチドからなる、ラッカーゼ:
(a)配列番号1に示すアミノ酸配列からなるポリペプチド;
(b)配列番号1に示すアミノ酸配列において、1個又は数個のアミノ酸が置換、付加、挿入又は欠失されてなるアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド;
(c)配列番号1に示すアミノ酸配列に対する配列同一性が70%以上のアミノ酸配列からなり、且つ、アルカリ域を含むpH領域で、前記(a)に示すポリペプチドと同等のラッカーゼ活性を有するポリペプチド。 - 請求項1に記載のラッカーゼをコードするDNA。
- 請求項2に記載のDNAを含む発現カセット又は組換えベクター。
- 請求項3に記載の発現カセット又は組換えベクターを用いて宿主を形質転換して得られる形質転換体。
- 請求項4に記載の形質転換体を培養する工程を含む、ラッカーゼの製造方法。
- 請求項1に記載のラッカーゼを含む酵素製剤。
- タンパク質の架橋剤として用いられる、請求項6に記載の酵素製剤。
- 飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材の酸化改質剤として用いられる、請求項6に記載の酵素製剤。
- タンパク質に、請求項1に記載のラッカーゼを作用させる工程を含む、架橋タンパク質の製造方法。
- 前記工程をアルカリ性条件下で行う、請求項9に記載の製造方法。
- 前記工程において、前記ラッカーゼに、3-(3,4-ジヒドロキシフェニル)アラニン、カテキン、及びカフェイン酸からなる群より選択されるメディエータを併用する、請求項9に記載の製造方法。
- 飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材に、請求項1に記載のラッカーゼを作用させる工程を含む、酸化改質された飲食品又は飲食品用素材、産業用素材又は産業廃棄成分、若しくは医薬又は科学分析用素材の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22828505.2A EP4361274A1 (en) | 2021-06-23 | 2022-06-23 | Laccase |
JP2023530122A JPWO2022270589A1 (ja) | 2021-06-23 | 2022-06-23 | |
CN202280034751.8A CN117321207A (zh) | 2021-06-23 | 2022-06-23 | 漆酶 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021104265 | 2021-06-23 | ||
JP2021-104265 | 2021-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022270589A1 true WO2022270589A1 (ja) | 2022-12-29 |
Family
ID=84544450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/025137 WO2022270589A1 (ja) | 2021-06-23 | 2022-06-23 | ラッカーゼ |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4361274A1 (ja) |
JP (1) | JPWO2022270589A1 (ja) |
CN (1) | CN117321207A (ja) |
WO (1) | WO2022270589A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214554A1 (ja) * | 2022-05-06 | 2023-11-09 | 天野エンザイム株式会社 | 植物性タンパク質含有組成物の増粘剤 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055628A2 (de) | 1997-06-06 | 1998-12-10 | Consortium für elektrochemische Industrie GmbH | Dns-sequenzen, expression dieser dns-sequenzen, durch die dns-sequenzen kodierte thermophile laccasen sowie deren verwendung |
JPH11276162A (ja) * | 1998-03-31 | 1999-10-12 | Amano Pharmaceut Co Ltd | 酵素による蛋白質の架橋法 |
JP2001069973A (ja) * | 1999-09-03 | 2001-03-21 | Daiwa Kasei Kk | アルカリラッカーゼおよびその生産方法 |
JP2001103989A (ja) | 1999-09-08 | 2001-04-17 | Givaudan Sa | ラッカーゼによる天然フレーバーの製造 |
JP2002171968A (ja) | 2000-09-26 | 2002-06-18 | Rengo Co Ltd | 耐熱性ラッカーゼおよびその製造方法 |
JP2003117569A (ja) * | 2001-06-29 | 2003-04-22 | Daiwa Kasei Kk | 蛍光増白剤を分解する方法 |
JP2004208503A (ja) * | 2002-12-26 | 2004-07-29 | Daiwa Kasei Kk | 新規アルカリラッカーゼ、その製造方法、及びその利用 |
-
2022
- 2022-06-23 CN CN202280034751.8A patent/CN117321207A/zh active Pending
- 2022-06-23 JP JP2023530122A patent/JPWO2022270589A1/ja active Pending
- 2022-06-23 EP EP22828505.2A patent/EP4361274A1/en active Pending
- 2022-06-23 WO PCT/JP2022/025137 patent/WO2022270589A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055628A2 (de) | 1997-06-06 | 1998-12-10 | Consortium für elektrochemische Industrie GmbH | Dns-sequenzen, expression dieser dns-sequenzen, durch die dns-sequenzen kodierte thermophile laccasen sowie deren verwendung |
JPH11276162A (ja) * | 1998-03-31 | 1999-10-12 | Amano Pharmaceut Co Ltd | 酵素による蛋白質の架橋法 |
JP2001069973A (ja) * | 1999-09-03 | 2001-03-21 | Daiwa Kasei Kk | アルカリラッカーゼおよびその生産方法 |
JP2001103989A (ja) | 1999-09-08 | 2001-04-17 | Givaudan Sa | ラッカーゼによる天然フレーバーの製造 |
JP2002171968A (ja) | 2000-09-26 | 2002-06-18 | Rengo Co Ltd | 耐熱性ラッカーゼおよびその製造方法 |
JP2003117569A (ja) * | 2001-06-29 | 2003-04-22 | Daiwa Kasei Kk | 蛍光増白剤を分解する方法 |
JP2004208503A (ja) * | 2002-12-26 | 2004-07-29 | Daiwa Kasei Kk | 新規アルカリラッカーゼ、その製造方法、及びその利用 |
Non-Patent Citations (4)
Title |
---|
DATABASE UNIPROTKB 25 April 2018 (2018-04-25), ANONYMOUS : "A0A2N3N6S4 · A0A2N3N6S4_9PEZI", XP093016729, retrieved from UNIPROT Database accession no. A0A2N3N6S4_9PEZI * |
MCKENZIE, T. ET AL., PLASMID, vol. 15, no. 2, 1986, pages 93 - 103 |
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250 |
YANGMIN GONG ET AL., JOURNAL OF BASIC MICROBIOLOGY, vol. 51, 2011, pages 666 - 672 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214554A1 (ja) * | 2022-05-06 | 2023-11-09 | 天野エンザイム株式会社 | 植物性タンパク質含有組成物の増粘剤 |
Also Published As
Publication number | Publication date |
---|---|
EP4361274A1 (en) | 2024-05-01 |
CN117321207A (zh) | 2023-12-29 |
JPWO2022270589A1 (ja) | 2022-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10941390B2 (en) | Protein deamidase | |
JP5643756B2 (ja) | バチルス・サーキュランス由来のβ−ガラクトシダーゼ | |
DK2593473T3 (en) | Asparaginase FROM Basidiomycetes | |
AU3253895A (en) | Microbial transglutaminases, their production and use | |
WO2022270589A1 (ja) | ラッカーゼ | |
WO2022270590A1 (ja) | ラッカーゼ | |
JPWO2009087826A1 (ja) | シュウ酸脱炭酸酵素の生産に利用される組換え発現プラスミドベクター及び組換え菌、並びに組換えシュウ酸脱炭酸酵素の生産方法 | |
JP4663631B2 (ja) | 放線菌由来のampデアミナーゼ及びその利用 | |
WO2020116331A1 (ja) | 改変型菊酸エステラーゼ | |
EP1205542B1 (de) | L-Aminosäure-Oxidase aus Rhodococcus-Arten | |
EP2126060B1 (en) | Novel lysyl oxidases | |
Stelkes-Ritter et al. | Purification and characterization of a newly screened microbial peptide amidase | |
WO2018025997A1 (ja) | ヘミセルラーゼ | |
JP4309681B2 (ja) | シイタケラッカーゼの調製法とフェノール性環境汚染物質の分解法 | |
WO2021200955A1 (ja) | コラゲナーゼ剤及びその用途 | |
JP2008005734A (ja) | アルカリホスファターゼ | |
WO2024071388A1 (ja) | 酵素剤及びその応用 | |
KR102405289B1 (ko) | 세팔로스포린 c 아실라제 활성을 가지는 폴리펩타이드 및 이의 용도 | |
WO2022244875A1 (ja) | 加工オート飲食品又は食品素材の製造方法 | |
JP4513967B2 (ja) | D−アミノアシラーゼの活性向上方法 | |
US20230416718A1 (en) | Thermotolerant protein glutaminase | |
JP7311496B2 (ja) | 改変型エステラーゼ及びその用途 | |
WO2021177392A1 (ja) | 変異型トランスグルタミナーゼ | |
JP4056369B2 (ja) | 耐熱性ラッカーゼ、その遺伝子およびその製造方法 | |
WO2023090461A1 (ja) | タンパク質脱アミド酵素 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22828505 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280034751.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023530122 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022828505 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022828505 Country of ref document: EP Effective date: 20240123 |